• Aucun résultat trouvé

Stability of 90 mg/ml cefuroxime sodium solution for administration by continuous infusion

N/A
N/A
Protected

Academic year: 2021

Partager "Stability of 90 mg/ml cefuroxime sodium solution for administration by continuous infusion"

Copied!
1
0
0

Texte intégral

(1)

Stability of 90 mg/mL Cefuroxime Sodium

Solution for Administration by Continuous

Infusion

S Streel1, C. Vercheval² , A-C. Servais³, M. Fillet³, T. Van Hees²

¹Department of Hospital Pharmacy, CHU Liège, Belgium ²Department of Clinical Pharmacy, CHU Liège, Belgium ³Department of Analysis of Medicines, CHU Liège, Belgium

INTRODUCTION

Cefuroxime, a β-lactam antibiotic, is usually prescribed as 1.5 g diluted to 50-100 mL of 0.9% saline 3 times per day.

Current understandings suggest that continuous infusions of β-lactam antibiotics increase pharmacokinetic /pharmacodynamic target attainment. However, this way of administration brings about some practical issues such as stability. Few articles showed the stability of cefuroxime sodium solutions of different concentrations but not at higher concentrations than 60 mg/mL.[1-2]

OBJECTIVE

To determine the stability of 90 mg/mL cefuroxime sodium solution (4.5 g dissolved in 50-mL 0.9% saline) stored in a polypropylene syringe at different storage conditions.

METHOD

Commercially vials of cefuroxime sodium (4.5 g total dose) were reconstituted and mixed with 50-mL 0.9% saline to produce 90 mg/mL solution in polypropylene syringes which were stored at 4°C, 25°C and 40°C. Cefuroxime sodium concentration was determined periodically over 14 days (days 0, 1, 2, 7, 14) using a stability-indicating HPLC method with UV detection. Reconstituted solutions were considered as stable as if antibiotic concentration remained at over 90% of the theoritical concentration.

RESULTS

The analytical results are summarized in table 1. Colour increased with time, heat and exposure to light. No precipitation was observed under any of the storage conditions.

Time

4°C

Light protected

25°C

Light protected

25°C

Exposed to light

40°C

Light protected

0 H

/

102.44 ± 1.97%

106.17 ± 2.77%

/

24 H

/

98.26 ± 1.06%

101.16 ± 1.06%

55.21 ± 0.73 %

48 H

/

93.68 ± 2.52%

90.60 ± 0.44%

/

168 H

97.89 ± 1.10%

76.94 ± 1.03%

59.91 ± 0.51 %

/

336 H

96.66 ± 0.84%

/

/

/

Table 1. Cefuroxime sodium concentrations (mean ± SD (%); n=3) in polypropylene

syringes at different storage conditions

DISCUSSION/ CONCLUSION

• This study has shown that a 90 mg/mL cefuroxime sodium infusion syringe is stable for 48 hours

with storage at 25°C protected or not from light, and for at least 14 days when stored at 4°C.

• In clinical practice, hospital pharmacists can safely prepare 4.5 g cefuroxime sodium in 50-mL 0.9%

saline polypropylene syringes that can be stored in a refrigerator for at least 14 days at 4°C.

• Physicians can safely use 90 mg/mL cefuroxime sodium solution as 24-hour infusion.

Références:

[1] ML Stiles et al., Stability of ceftazidime (with arginine) and of cefuroxime sodium in infusion pump reservoirs, American Journal of hospital pharmacy, 1992 ;

[2]D Gupta, Chemical stability of cefuroxime sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene yringes for pediatric use, International Journal of Pharmaceutical Compounding, 2003.

Références

Documents relatifs

SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN.. Keep out of the sight and reach

The overall efficacy of the bimatoprost 0.03 %/timolol 0.5 % eye drops combination in the treatment of patients with open-angle glaucoma or ocular hypertension

 le 1 er mai 2017 dans l’indication « traitement des patients présentant un carcinome urothélial localement avancé ou métastatique dont la maladie a progressé pendant ou

L’ATUc Durvalumab a pris fin en France le 28 octobre 2018 et depuis le 29 octobre 2018, la spécialité IMFINZI (durvalumab), 50 mg/ml solution à diluer pour perfusion est

En accord avec l’ANSM, dans le cadre de la pandémie de COVID-19, le laboratoire Medipha Santé met à disposition à titre exceptionnel et transitoire, la spécialité Atracurium

En accord avec l’ANSM, dans le cadre de la pandémie de COVID-19, les laboratoires Roche mettent à disposition à titre exceptionnel et transitoire, la spécialité RoActemra 20

Intravenous or intramuscular administration of the recommended dose of 2 mg to 4 mg of ATIVAN Injection to adult patients is followed by dose-related effects of sedation (sleepiness

Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ;